Education
About Us
Working with TipRanks
Follow Us
Aarti Drugs Limited (IN:AARTIDRUGS)
:AARTIDRUGS
AARTIDRUGS Stock Chart & Stats
₹404.80
-₹2.25(-0.50%)
At close: 4:00 PM EST
₹404.80
-₹2.25(-0.50%)
Day’s Range― - ―
52-Week Range₹312.50 - ₹574.95
Previous CloseN/A
Volume68.36K
Average Volume (3M)11.99K
Market Cap
₹31.74B
Enterprise Value₹37.41B
Total Cash (Recent Filing)₹245.40M
Total Debt (Recent Filing)₹5.73B
Price to Earnings (P/E)23.2
Beta1.09
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)4.40
Shares Outstanding91,270,000
10 Day Avg. Volume14,342
30 Day Avg. Volume11,994
Financial Highlights & Ratios
PEG Ratio-16.53
Price to Book (P/B)2.30
Price to Sales (P/S)1.32
P/FCF Ratio46.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹480.00Price Target Upside18.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)21.5
Revenue Forecast (FY)₹26.07B
Bulls Say, Bears Say
Bulls Say
B2B API & Specialty Chemicals ManufacturingAarti Drugs' core B2B manufacturing model—APIs, intermediates and specialty chemicals—provides durable revenue streams tied to industrial demand. Multi-product plants and export reach help diversify end markets and improve long-term asset utilization versus single-product peers.
Balance Sheet StabilityManageable leverage and a consistent return on equity give the company financial resilience. A moderate debt profile supports sustainable interest coverage and capacity for targeted reinvestment or selective M&A without materially impairing long-term solvency.
Earnings ImprovementSubstantial EPS growth indicates operational leverage or efficiency gains that improve profit per share over time. If sustained, higher EPS supports reinvestment, debt reduction or dividend policy and signals management can improve underlying profitability despite revenue headwinds.
Bears Say
Recent Revenue DeclineA recent drop in revenue points to demand weakness, pricing pressure, or lost volumes; unless structural market share or new product gains reverse this, persistent revenue declines erode scale economics and limit the company's ability to fund long-term growth initiatives.
Weak Free Cash Flow TrendsDeclining free cash flow and variability in operating cash flow reduce financial flexibility for capex, working capital and debt repayment. Persistent FCF weakness constrains strategic investments and raises risk around funding cycles and resilience to industry downturns.
Margin VolatilityFluctuating EBIT/EBITDA margins signal inconsistent cost pass-through, input cost exposure or mix shifts. Margin unpredictability undermines earnings visibility, complicates capital allocation and raises persistent execution risk for maintaining long-term profitability.
Aarti Drugs Limited News
AARTIDRUGS FAQ
What was Aarti Drugs Limited’s price range in the past 12 months?
Aarti Drugs Limited lowest stock price was ₹312.50 and its highest was ₹574.95 in the past 12 months.
What is Aarti Drugs Limited’s market cap?
Aarti Drugs Limited’s market cap is ₹31.74B.
When is Aarti Drugs Limited’s upcoming earnings report date?
Aarti Drugs Limited’s upcoming earnings report date is May 11, 2026 which is in 58 days.
How were Aarti Drugs Limited’s earnings last quarter?
Aarti Drugs Limited released its earnings results on Feb 03, 2026. The company reported ₹4.4 earnings per share for the quarter, missing the consensus estimate of ₹4.9 by -₹0.5.
Is Aarti Drugs Limited overvalued?
According to Wall Street analysts Aarti Drugs Limited’s price is currently Undervalued.
Does Aarti Drugs Limited pay dividends?
Aarti Drugs Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Aarti Drugs Limited dividends here
What is Aarti Drugs Limited’s EPS estimate?
Aarti Drugs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Drugs Limited have?
Aarti Drugs Limited has 91,270,000 shares outstanding.
What happened to Aarti Drugs Limited’s price movement after its last earnings report?
Aarti Drugs Limited reported an EPS of ₹4.4 in its last earnings report, missing expectations of ₹4.9. Following the earnings report the stock price went up 2.152%.
Which hedge fund is a major shareholder of Aarti Drugs Limited?
Currently, no hedge funds are holding shares in IN:AARTIDRUGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
AARTIDRUGS Stock 12 Month Forecast
Average Price Target
₹480.00
▲(18.58% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―